Turnip
Well-Known Member
Could be. But there are already approved SSRIs on the market:
* Citalopram (Celexa)
* Escitalopram (Lexapro)
* Fluoxetine (Prozac)
* Paroxetine (Paxil, Pexeva)
* Sertraline (Zoloft)
* Paxil CR
So far that's six different brands. What are the odds a seventh new brand might set the other six apart?
Isn't that 7 brands already (6 drugs)? If it's an SSRI it'd be likely one of those drugs/drug companies trying to find a new market, I've already stated that a new drug seems less likely than an existing drug. If a one of those brands could get an on-label use of making people on the spectrum more "social", well I imagine evil-drug-co stereotypes dream of things like that (all the while having their eye's bulge in the shape of dollar signs cartoon style)
EDIT: just saw your edit, to clarify "marketing" was not a part of what I was thinking (drug companies can not advertise to the public where I'm from so marketing as you have in the US didn't even occur to me). My thinking was about off-label usage vs. on-label usage, and proving something has some effect vs. hypothesising it should... your average GP can prescribe say Zoloft for depression where I'm from but wouldn't dream of prescribing it for an off-label treatment for anything else.
Last edited: